At the ASCO conference, Prof Dr George Lau, a renowned digestive oncologist from the Humanity and Health Clinical Trial Center in Hong Kong, presented an exploratory post hoc analysis derived from the phase 3 HIMALAYA study. This study focused on patients diagnosed with unresectable hepatocellular carcinoma (uHCC). The analysis revealed that a single dose of tremelimumab combined with regular interval durvalumab (STRIDE regimen) demonstrated a significant improvement in overall survival compared to sorafenib, a standard treatment for uHCC.
In addition, Prof Lau discussed the temporal patterns of immune-mediated adverse events associated with the STRIDE regimen. This analysis shed light on the timing and characteristics of immune-related side effects that occurred during the treatment course.
With the educational support of:
